Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/23/2019 |
| Start Date: | March 2011 |
| End Date: | September 1, 2017 |
Comparison of Creatinine Clearance Calculation Methods for Estimation of Glomerular Filtration Rate in Patients Receiving High-Dose Methotrexate
The purpose of this study is to compare different estimates of calculating creatinine
clearance by mathematical formula and compare them to creatinine clearance based on a timed
urine collection in patients who received high-dose methotrexate for the treatment of primary
CNS lymphoma or CNS involvement of systemic lymphoma.
clearance by mathematical formula and compare them to creatinine clearance based on a timed
urine collection in patients who received high-dose methotrexate for the treatment of primary
CNS lymphoma or CNS involvement of systemic lymphoma.
We intend to perform a retrospective chart review to identify a serum creatinine-based
equation that gives the best estimate of CrCl as compared with an equation derived from a
24-hour urine collection.
Study subjects will be identified using the Brigham and Women's Hospital and Dana-Farber
Cancer Institute's Adult Pharmacy systems to identify patients who received high-dose
methotrexate. Data will be collected starting with December 31, 2010 and proceeding
chronologically backwards until the target enrollment of 40 patients is reached.
equation that gives the best estimate of CrCl as compared with an equation derived from a
24-hour urine collection.
Study subjects will be identified using the Brigham and Women's Hospital and Dana-Farber
Cancer Institute's Adult Pharmacy systems to identify patients who received high-dose
methotrexate. Data will be collected starting with December 31, 2010 and proceeding
chronologically backwards until the target enrollment of 40 patients is reached.
Inclusion Criteria:
- Age >/= 18 years
- Received high-dose methotrexate therapy at Dana-Farber Cancer Institute/Brigham and
Women's Hospital for the treatment of primary CNS lymphoma or CNS involvement of
systemic lymphoma
- Available timed urine collection within 1 week of HDMTX
Exclusion Criteria:
- Receiving high-dose methotrexate for indications other than primary CNS lymphoma or
CNS involvement of systemic lymphoma
- Documented viral hepatitis
We found this trial at
1
site
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
